Dr. Reddy's recalls some lots of heartburn drug in U.S
MUMBAI (Reuters) - Generic drugmaker Dr. Reddy's Laboratories Ltd (REDY.NS) is recalling about 58,656 bottles of the heartburn drug lansoprazole in the United States due to a microbial contamination, the U.S. Food and Drug Administration said.
It was classified as a "Class II" recall which indicates a remote chance of severe adverse consequences or death due to the product flaw.
While product recalls are not uncommon, the FDA announcement comes amid a string of quality problems for Indian drug makers.
In a weekly report, the U.S. regulator also announced it was banning imports from Sun Pharmaceutical Industries (SUN.NS) Karkhadi manufacturing plant in Gujarat.
And just last week, the FDA disclosed that products made by Sun Pharma and Ranbaxy Laboratories (RANB.NS) were being recalled.
Dr. Reddy's voluntary recall of lansoprazole delayed release capsules, a generic version of Swiss drugmaker Novartis' (NOVN.VX) drug Prevacid 24 HR, began on January 3, 2014, the FDA said on its website.
A spokesman for Dr. Reddy's was not immediately available to comment.
(Reporting by Zeba Siddiqui; Editing by Edwina Gibbs)
- Tweet this
- Share this
- Digg this
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- Modi slams whispering campaign against Rajnath Singh
- Insight - Islamic State turns radical Islam on Syria Muslims
- Sensex, Nifty mark record closing high on Euro zone stimulus talk
- How Pakistan's Sharif stumbled into protests crisis
COAL BLOCK ALLOCATIONS
A Supreme Court ruling this week that India's decades-old method of granting coal mining concessions is illegal could herald much-needed reforms in a sector long dogged by the inability of state-run Coal India to raise output fast enough. Read
Kleiner to invest in messaging startup Snapchat at near-$10 bln valuation - report. Full Article